Manuel Portero-Otin

Dr. Manuel Portero-Otin


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Advances in Nutrition
Verified
Journal Article
Open access
PDF file
Jaime UribarriJaime Uribarri
Jaime Uribarri
Dolores del CastilloDolores del Castillo
Dolores del Castillo
MMMaría Pía de la Maza
María Pía de la Maza
RFRosana Filip
Rosana Filip
AGAlejandro Gugliucci
Alejandro Gugliucci
MGMa Eugenia Garay-Sevilla
Ma Eugenia Garay-Sevilla
Over the past 2 decades there has been increasing evidence supporting an important contribution from food-derived advanced glycation end products (AG

12 October 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MRM. Mar Rodríguez
M. Mar Rodríguez
DPDaniel Pérez
Daniel Pérez
FCFELIPE JAVIER CHAVES
FELIPE JAVIER CHAVES
EEEduardo Esteve
Eduardo Esteve
PMPablo Marin-Garcia
Pablo Marin-Garcia
JFJosé M. Fernandez-Real
José M. Fernandez-Real
The human intestine is home to a diverse range of bacterial and fungal species, forming an ecological community that contributes to normal physiology and disease susceptibility. Here, the fungal microbiota (mycobiome) in obese and non-obese subjects was characterized using Internal Transcribed Spacer (ITS)-based sequencing. The results demonstrate that obese patients could be discriminated by their specific fungal composition, which also distinguished metabolically “healthy” from “unhealthy” obesity. Clusters according to genus abundance co-segregated with body fatness, fasting triglycerides and HDL-cholesterol. A preliminary link to metabolites such as hexadecanedioic acid, caproic acid and N-acetyl-L-glutamic acid was also found.Mucor racemosusandM. fuscuswere the species more represented in non-obese subjects compared to obese counterparts. Interestingly, the decreased relative abundance of theMucorgenus in obese subjects was reversible upon weight loss. Collectively, these findings suggest that manipulation of gut mycobiome communities might be a novel target in the treatment of obesity.

1 January 2015
Verified
Book Chapter
Closed access
ANAlba Naudí
Alba Naudí
RCRosanna Cabré
Rosanna Cabré
MFMariona Jove Font
Mariona Jove Font
VAVictoria Ayala
Victoria Ayala
HGHugo Gonzalo
Hugo Gonzalo
RPReinald Pamplona
Reinald Pamplona

1 July 2014 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Closed access
MFMariona Jove Font
Mariona Jove Font
MPManuel Portero-Otin
Manuel Portero-Otin
ANAlba Naudí
Alba Naudí
IFIsidre Ferrer
Isidre Ferrer
RPReinald Pamplona
Reinald Pamplona
Neurons in the mature human central nervous system (CNS) perform a wide range of motor, sensory, regulatory, behavioral, and cognitive functions. Such diverse functional output requires a great diversity of CNS neuronal and non-neuronal populations. Metabolomics encompasses the study of the complete set of metabolites/low-molecular-weight intermediates (metabolome), which are context-dependent and vary according to the physiology, developmental state, or pathologic state of the cell, tissue, organ, or organism. Therefore, the use of metabolomics can help to unravel the diversity-and to disclose the specificity-of metabolic traits and their alterations in the brain and in fluids such as cerebrospinal fluid and plasma, thus helping to uncover potential biomarkers of aging and neurodegenerative diseases. Here, we review the current applications of metabolomics in studies of CNS aging and certain age-related neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis. Neurometabolomics will increase knowledge of the physiologic and pathologic functions of neural cells and will place the concept of selective neuronal vulnerability in a metabolic context.

1 April 2014 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
RMRenzo Mancuso
Renzo Mancuso
JMJaume del Valle Macià
Jaume del Valle Macià
LMLaura Modol
Laura Modol
AMAnna Martinez
Anna Martinez
AGAna B Granado-Serrano
Ana B Granado-Serrano
XNXavier Navarro
Xavier Navarro

11 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AGA. B. Granado-Serrano
A. B. Granado-Serrano
MMMeritxell Martin
Meritxell Martin
VSV. Sánchez
V. Sánchez
MSM. Riart Solans
M. Riart Solans
RBR. Berdún
R. Berdún
Jose SerranoJose Serrano
Jose Serrano
Gut microbiota has been suggested to affect lipid metabolism. The objective of this study was to characterize the faecal microbiota signature and both short chain fatty acids (SCFAs) and bile acids (BA) profile of hypercholesterolemic subjects. Microbiota composition, SCFAs, BA and blood lipid profile from male volunteers with hypercholesterolemia (HC) and normocholesterolemia (NC) were determined by 16S rDNA sequencing, HPLC, GC and NMR, respectively. HC subjects were characterized by having lower relative abundance of Anaeroplasma (0.002% vs 0.219%, p-value = 0.026) and Haemophilus (0.041% vs 0.078%, p-value = 0.049), and higher of Odoribacter (0.51% vs 0.16%; p-value = 0.044). Correlation analysis revealed that Anaeroplasma and Haemophilus were associated to an unfavourable lipid profile: they correlated negatively to cholesterol and triglycerides related biomarkers and the ratio total to high density lipoprotein (HDL) cholesterol, and positively to HDL size. Odoribacter displayed an opposite behaviour. Faecal SCFAs profile revealed higher abundance of isobutyric (2.76% vs 0.82%, p-value = 0.049) and isovaleric acid (1.32% vs 0.06%, p-value = 0.016) in HC. Isobutyric acid correlated positively with Odoribacter and lipid parameters indicative of an unfavourable profile. BA profile did not show differences between groups. It was concluded that HC subjects showed a particular faecal bacterial signature and SCFAs profile associated with their lipid profile.